AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We are advancing the development of our proprietary product candidates, and where applicable, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights.

Our most advanced wholly owned antibody programs, imsidolimab, rosnilimab and ANB032, are designed to modulate therapeutic targets that are genetically associated with human inflammatory disorders.

We are developing our imsidolimab product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis (GPP) and hidradenitis suppurativa.

Our second wholly owned program rosnilimab, an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases.

Our third wholly owned program is an anti-BTLA modulator antibody, known as ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro.

Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.

Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with GlaxoSmithKline (GSK).